PMID- 29516130
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20181114
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Print)
IS  - 1619-7070 (Linking)
VI  - 45
IP  - 10
DP  - 2018 Sep
TI  - Radioembolisation in patients with hepatocellular carcinoma that have previously 
      received liver-directed therapies.
PG  - 1721-1730
LID - 10.1007/s00259-018-3968-5 [doi]
AB  - PURPOSE: Radioembolisation is part of the multimodal treatment of hepatocellular 
      carcinoma (HCC) at specialist liver centres. This study analysed the impact of 
      prior treatment on tolerability and survival following radioembolisation. 
      METHODS: This was a retrospective analysis of 325 consecutive patients with a 
      confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin 
      microspheres at eight European centres between September 2003 and December 2009. 
      The decision to treat was based on the clinical judgement of multidisciplinary 
      teams. Patients were followed from the date of radioembolisation to last contact 
      or death and the nature and severity of all adverse events (AEs) recorded from 
      medical records. RESULTS: Most radioembolisation candidates were Child-Pugh class 
      A (82.5%) with multinodular HCC (75.9%) invading both lobes (53.1%); 56.3% were 
      advanced stage. Radioembolisation was used first-line in 57.5% of patients and 
      second-line in 34.2%. Common prior procedures were transarterial 
      (chemo)embolisation therapies (27.1%), surgical resection/transplantation (17.2%) 
      and ablation (8.6%). There was no difference in AE incidence and severity between 
      prior treatment subgroups. Median (95% confidence interval [CI]) survival 
      following radioembolisation was similar between procedure-naive and prior 
      treatment groups for Barcelona Clinic Liver Cancer (BCLC) stage A: 22.1 months 
      (15.1-45.9) versus 30.9 months (19.6-46.8); p = 0.243); stage B: 18.4 months 
      (11.2-19.4) versus 22.8 months (10.9-34.2); p = 0.815; and stage C: 8.8 months 
      (7.1-10.8) versus 10.8 months (7.7-12.6); p = 0.976. CONCLUSIONS: 
      Radioembolisation is a valuable treatment option for patients who relapse 
      following surgical, ablative or vascular procedures and remain suitable 
      candidates for this treatment.
FAU - Sangro, Bruno
AU  - Sangro B
AD  - Liver Unit, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica 
      en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), Avda. Pio XII, 36, 
      31008, Pamplona, Spain. bsangro@unav.es.
FAU - Maini, Carlo Ludovico
AU  - Maini CL
AD  - Nuclear Medicine, IFO Regina Elena National Cancer Institute, Rome, Italy.
FAU - Ettorre, Giuseppe Maria
AU  - Ettorre GM
AD  - General Surgery and Transplantation Unit, San Camillo Hospital, Rome, Italy.
FAU - Cianni, Roberto
AU  - Cianni R
AD  - Interventional Radiology, Ospedale S.M.Goretti, Latina, Italy.
FAU - Golfieri, Rita
AU  - Golfieri R
AD  - Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
FAU - Gasparini, Daniele
AU  - Gasparini D
AD  - Diagnostic and Interventional Radiology, Azienda Ospedaliera S. M. della 
      Misericordia, Udine, Italy.
FAU - Ezziddin, Samer
AU  - Ezziddin S
AD  - Nuclear Medicine, Universitatsklinik Bonn, Bonn, Germany.
FAU - Paprottka, Philipp M
AU  - Paprottka PM
AD  - Interventional Radiology, LMU Klinikum der Universitat Munchen, Munich, Germany.
FAU - Fiore, Francesco
AU  - Fiore F
AD  - Onco Interventional Radiology, Istituto Tumori Pascale, Naples, Italy.
FAU - Van Buskirk, Mark
AU  - Van Buskirk M
AD  - Data Reduction LLC, 472 State Route 24, Chester, NJ, USA.
FAU - Bilbao, Jose Ignacio
AU  - Bilbao JI
AD  - Interventional Radiology, Clinica Universidad de Navarra, Pamplona, Spain.
FAU - Salvatori, Rita
AU  - Salvatori R
AD  - Nuclear Medicine, Ospedale S.M.Goretti, Latina, Italy.
FAU - Giampalma, Emanuela
AU  - Giampalma E
AD  - Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
FAU - Geatti, Onelio
AU  - Geatti O
AD  - Nuclear Medicine, Azienda Ospedaliera S. M. della Misericordia, Udine, Italy.
FAU - Wilhelm, Kai
AU  - Wilhelm K
AD  - Department of Radiology, University of Bonn, Bonn, Germany.
FAU - Hoffmann, Ralf Thorsten
AU  - Hoffmann RT
AD  - Interventional Radiology, LMU Klinikum der Universitat Munchen, Munich, Germany.
FAU - Izzo, Francesco
AU  - Izzo F
AD  - Hepatobiliary Surgery, Istituto Tumori Pascale, Naples, Italy.
FAU - Inarrairaegui, Mercedes
AU  - Inarrairaegui M
AD  - Liver Unit, Clinica Universidad de Navarra, and Centro de Investigacion Biomedica 
      en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), Avda. Pio XII, 36, 
      31008, Pamplona, Spain.
FAU - Urigo, Carlo
AU  - Urigo C
AD  - Interventional Radiology, Ospedale S.M.Goretti, Latina, Italy.
FAU - Cappelli, Alberta
AU  - Cappelli A
AD  - Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
FAU - Vit, Alessandro
AU  - Vit A
AD  - Interventional Radiology, IFO Regina Elena National Cancer Institute, Rome, 
      Italy.
FAU - Ahmadzadehfar, Hojjat
AU  - Ahmadzadehfar H
AD  - Nuclear Medicine, Universitatsklinik Bonn, Bonn, Germany.
FAU - Jakobs, Tobias Franz
AU  - Jakobs TF
AD  - Interventional Radiology, LMU Klinikum der Universitat Munchen, Munich, Germany.
FAU - Sciuto, Rosa
AU  - Sciuto R
AD  - Nuclear Medicine, IFO Regina Elena National Cancer Institute, Rome, Italy.
FAU - Pizzi, Giuseppe
AU  - Pizzi G
AD  - Interventional Radiology, IFO Regina Elena National Cancer Institute, Rome, 
      Italy.
FAU - Lastoria, Secondo
AU  - Lastoria S
AD  - Nuclear Medicine, Istituto Tumori Pascale, Naples, Italy.
CN  - European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY)
LA  - eng
PT  - Journal Article
DEP - 20180307
PL  - Germany
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Hepatocellular/*radiotherapy
MH  - *Embolization, Therapeutic/adverse effects
MH  - Female
MH  - Humans
MH  - Liver/*radiation effects
MH  - Liver Neoplasms/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Safety
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC6097757
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Radioembolisation
OT  - Selective internal radiation therapy
OT  - Yttrium-90 resin microspheres
COIS- CONFLICTS OF INTEREST: Dr. Sangro and Dr. Van Buskirk are consultants for Sirtex 
      Medical. The remaining authors have no relevant affiliations or financial 
      involvement with any organisation or entity with a financial interest in or 
      financial conflict with the subject matter or materials discussed in the 
      manuscript. ETHICAL APPROVAL: All procedures performed in studies involving human 
      participants were in accordance with the ethical standards of the institutional 
      and/or national research committee and with the 1964 Helsinki declaration and its 
      later amendments or comparable ethical standards. For this type of study formal 
      consent is not required.
EDAT- 2018/03/09 06:00
MHDA- 2018/11/06 06:00
PMCR- 2018/03/07
CRDT- 2018/03/09 06:00
PHST- 2017/11/20 00:00 [received]
PHST- 2018/02/01 00:00 [accepted]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/07 00:00 [pmc-release]
AID - 10.1007/s00259-018-3968-5 [pii]
AID - 3968 [pii]
AID - 10.1007/s00259-018-3968-5 [doi]
PST - ppublish
SO  - Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1721-1730. doi: 
      10.1007/s00259-018-3968-5. Epub 2018 Mar 7.